Cost-effectiveness of mepolizumab vs anti-interleukin-5/5r biologic therapies for the treatment of adults with severe asthma with an eosinophilic phenotype: a Chilean healthcare system perspective
Mepolizumab offers greater efficacy and cost savings compared to benralizumab and reslizumab for eosinophilic asthma, providing essential insights for improving asthma management and informing healthcare policies in Chile.
Authors
- Vanina Giovini
- Manuel Espinoza (ORCID: https://orcid.org/0000-0001-9564-9512)
- Carmen Martı́nez (ORCID: https://orcid.org/0000-0001-7226-9154)
- Felipe Moraes dos Santos (ORCID: https://orcid.org/0000-0003-1191-7685)
- José A. Romero
- Carlos Balmaceda
Institutions
- Pontificia Universidad Católica de Chile (CL)
- Colegio Médico de Chile (CL)
- Epsilon Systems (United States) (US)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-06-18
- DOI
- https://doi.org/10.1080/13696998.2025.2520701
- Citations
- 1
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.16
Funders
- GlaxoSmithKline foundation